|
WO2020111212A1
|
|
Agent for improving cytokine release syndrome, etc.
|
|
WO2007013696A1
|
|
Anti-tumor agent comprising 6'-amidino-2'-naphthyl4- guanidinobenzoate or salt thereof
|
|
WO2005120491A1
|
|
Remedy or preventive for inflammatory bowel disease
|
|
EP1767531A1
|
|
Medicinal compositions containing 6-hydroxybenzbromarone or salts thereof
|
|
AU3673800A
|
|
Novel naphthalene derivatives
|
|
WO0177082A1
|
|
Naphthalene derivatives
|
|
AU3673700A
|
|
Naphthalene derivatives
|
|
WO0177076A1
|
|
Novel naphthalene derivatives
|
|
AU1800000A
|
|
Medicine container and syringe
|
|
AU4058399A
|
|
Naphthalene derivatives
|
|
WO9963084A1
|
|
T cell antigen receptor sequences specific to arthrosis deformans
|
|
AU2231397A
|
|
Thiazolidine-2,4-dione derivatives
|
|
KR100258496B1
|
|
Substituted amidinonaphthyl ester derivative
|
|
WO9620920A1
|
|
Amidinonaphthyl ester derivative
|
|
WO9620706A1
|
|
Thrombolytic agent
|
|
CZ212897A3
|
|
Thrombolytic agents
|
|
CA2209619A1
|
|
Thrombolytic agents
|
|
CA2197872A1
|
|
Spontaneously diabetic rat
|
|
EP0781506A1
|
|
Spontaneously diabetic rat
|
|
AU3574993A
|
|
Organ preserving fluid
|
